Personalized cancer treatment now available through innovative simulation application
CancerMate, a groundbreaking simulation app, is set to transform the landscape of personalized cancer treatment. Developed by iBMB Srls, the app utilizes the powerful capabilities of COMSOL Multiphysics software to model the proliferation of cancer cells and predict the response to treatment in patients with nonmetastatic triple-negative breast cancer (TNBC).
A User-Friendly Tool for Oncologists and Researchers
The CancerMate app offers an intuitive user interface, making it accessible for oncologists and pharmaceutical researchers. Its simulation capabilities provide valuable insights into personalized cancer treatment, particularly for TNBC, a subtype of breast cancer that is often challenging to treat due to the absence of targeted therapies.
Simulating Tumor Progression and Response to Therapy
CancerMate focuses on simulating the proliferation of cancer cells in TNBC patients and virtually quantifying lesion volumes before neoadjuvant LYNPARZA® chemotherapy. After computing, the app displays the numerical results for the predicted clinical lesion values and a graphic showing the progress of the predicted cancer lesion volume and the integrated drug concentration.
Personalized Pharmacodynamic Efficiency
The app uses virtual biomarkers to supplement or predict traditional clinical biomarkers. These biomarkers, such as tumor-infiltrating lymphocytes (TILs) and protein Ki67, are integrated into the app's mathematical model. By applying these biomarkers to a set of equations that describe tumor growth and response to treatment over time, CancerMate helps oncologists adjust therapeutic strategies according to the results from the app.
Validated for Clinical Use
The CancerMate app has been validated against data from a clinical experiment involving LYNPARZA® treatment for nonmetastatic TNBC. This validation ensures the app's accuracy and reliability in predicting tumor volume evolution and optimizing therapeutic interventions.
A Step Towards Personalized Oncology
As a tool for predictive oncology, CancerMate can help clinicians assess and monitor tumor lesion volumes, potentially reducing the length of unnecessary treatment. By providing a more precise and patient-specific approach to cancer treatment, CancerMate is a significant step towards personalized oncology.
According to Gianpaolo Ruocco, CEO of iBMB Srls, CancerMate allows doctors to run virtual scenarios, reducing the burden on patients and treatment costs. The current version of CancerMate is ready for implementation in a clinical setting for TNBC treated with LYNPARZA®, and its underlying technology could be trained to cover more breast cancer subtype-therapy pairings and extended to other types of cancer and drug products.
In summary, CancerMate is a powerful tool that leverages the capabilities of COMSOL Multiphysics software to model tumor behavior and treatment response in nonmetastatic TNBC patients. This supports prediction of tumor volume evolution and optimization of therapeutic interventions, paving the way for a more personalized approach to cancer treatment.
- The numerical results and graphical representation provided by the CancerMate app shine a light on the progression of breast cancer lesions, particularly for nonmetastatic triple-negative breast cancer (TNBC), offering insights to both oncologists and researchers.
- By applying artificial intelligence (AI) and measurable biomarkers, such as tumor-infiltrating lymphocytes (TILs) and protein Ki67, the CancerMate app aims to improve the prediction and understanding of the response to treatment in cancer patients.
- The app's underlying technology, COMSOL Multiphysics software, has been validated against clinical data, ensuring its accuracy and reliability in predicting tumor evolution and optimizing treatment plans for patients with TNBC and LYNPARZA® therapy.
- By streamlining the simulation process, CancerMate can enhance health-and-wellness outcomes for patients with various medical-conditions, including cancer, and facilitate the development of targeted medtech solutions in the field of medical science and technology.
- In the quest for personalized medicine, CancerMate represents a significant leap forward in cancer treatment, as it enables a more precise and patient-specific approach that could transform industrial medtech landscape and cater to a broader array of cancer subtypes and therapy pairings.
